Zometa in therapy for bone metastases of prostate cancer during androgenic deprivation (Results of Russian multicenter study)
| Autor: | O. B. Karyakin, B. P. Matveev, V. B. Matveev, I. G. Rusakov, O. B. Loran, Ye. I. Veliyev, L. V. Shaplygin, B. V. Bukharkin, V. A. Biryukov, N. G. Minayeva, A. A. Atayev, V. M. Shelepova, M. I. Karelin, D. G. Prokhorov, Yu. N. Khrizman, V. K. Shakurov, E. F. Abdrakhmanov, V. N. Zhuravlev, A. V. Zyryanov, V. O. Mager, P. A. Karnaukh |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Onkourologiâ, Vol 3, Iss 2, Pp 56-60 (2020) |
| ISSN: | 1996-1812 1726-9776 |
| Popis: | Introduction: Hormonal therapy is the method of choice in treating disseminated prostate cancer. Chronic androgenic suppression causes a reduction in bone mineral density. The most common complications of bone metastases are pathological fractures, spinal cord compression, pain, etc.Methods: A multicenter study (11 clinics of Russia) assessing the efficacy of Zometa in preventing skeletal complications of bone metastases was conducted in 2004—2005. Zometa was administered intravenously at a dose of 4 mg every 3Р4 weeks with androgenic deprivation. Its objective effect was evaluated in 70 patients. Changes in bone mineral density were evaluated by densitometry.Results: Complete pain relief was achieved in 73% of the patients; after therapy 86% of the patients had 0—1 WHO activity status score, 97% of the patients had no bone complications. The level of bone resorption marker β-Cross-Laps decreased to the normal values in 51% of the patients.Conclusion: The study has provided an evidence of the efficacy of Zometa and the necessity of using this drug in complex therapy for bone metastases of prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|